EVALUATION OF OVERALL TOXICITY OF HIGH-DOSAGE METHOTREXATE REGIMENS

被引：24

作者：

PEREZ, C ^{[1
]}

SUTOW, WW ^{[1
]}

WANG, YM ^{[1
]}

HERSON, J ^{[1
]}

机构：

[1] UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DEPT PEDIAT,HOUSTON,TX 77030

来源：

MEDICAL AND PEDIATRIC ONCOLOGY | 1979年 / 6卷 / 03期

关键词：

chemotherapy; methotrexate; osteosarcoma; toxicity;

D O I：

10.1002/mpo.2950060306

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The occurrence of overall toxicity was analyzed for 43 patients with osteosarcoma who received 349 high‐dosage courses of methotrexate (HD‐MTX) with citrovorum factor (Leukovorin) „rescue” (CF). The dosages of HD‐MTX ranged from 50 to 350 mg/kg. Overall toxicity was assessed on the basis of five manifestations of toxicity: stomatitis, dermatitis, myelosuppression, liver dysfunction, and kidney function abnormalities. The great majority (91.4%) of the infusions were well tolerated, but 8.6% were associated with moderate or severe toxicity. Stomatitis and serum glutamic‐oxaloacetic transaminase (SGOT) changes were the most frequent postinfusion findings. Three patients died from causes related to MTX toxicity. Dose, age, sex, and number of prior infusions were investigated by logistic regression analysis for prognostic effect on frequency of moderate to severe overall toxicity. Age and number of prior infusions had significant (P < 0.06) effects on overall toxicity. Patients older than 15 years with greater than 10 prior infusions constituted the „high risk” group with a risk of moderate to severe toxicity 6.3 times that of the younger patients with fewer than 10 infusions. Copyright © 1979 Wiley‐Liss, Inc., A Wiley Company

引用

页码：219 / 228

页数：10

共 20 条

[1]

Bleyer AW, The clinical pharmacology of methotrexate. New applications of an old drug, Cancer, 41, pp. 36-51, (1978)

[2]

pp. 6-73, (1975)

[3]

Von Hoff DD, Penta JS, Helman LJ, Slavik M, Incidence of drug‐related deaths secondary to highdose methotrexate and citrovorum factor adminstration, Cancer Treat Rep, 61, (1977)

[4]

Wang Y-M, Lantin E, Sutow WW, Methotrexate in blood, urine and cerebrospinal fluid of children receiving high doses by infusion, Clin Chem, 22, pp. 1053-1056, (1976)

[5]

Fleiss J, Statistical Methods for Rates and Proportions, (1973)

[6]

Lee ET, A computer program for linear logistic regression analysis, Comput Programs Biomed, 4, pp. 80-92, (1974)

[7]

Jaffe N, Traggis D, Toxicity of high‐dose methotrexate (NSC‐740) and citrovorum factor (NSC‐3590) in osteogenic sarcoma, Cancer Treat Rep (pt 3), 6, pp. 31-36, (1975)

[8]

Pratt CB, Roberts DW, Shanks EC, Warmath EL, Clinical trials and pharmacokinetics of intermittent high‐dose methotrexate–“leucovorin rescue” for children with malignant tumors, Cancer Res, 34, pp. 3326-3331, (1974)

[9]

Rosen G, Suwansirikul S, Kwon C, Tan C, Wu SJ, Beattie EJ, Murphy ML, High‐dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma, Cancer, 33, pp. 1151-1163, (1974)

[10]

Chan H, Evans WE, Pratt CB, Recovery from toxicity associated with high‐dose methotrexate: Prognostic factors, Cancer Treat Rep, 61, pp. 797-804, (1977)

← 1 2 →